Centivax

San Francisco, United States Founded: 2019 • Age: 7 yrs
Drug discovery services are provided to pharmaceutical and biotech clients.
Annual revenue - Latest available
Total funding $92.0M 5 rounds
Employees - Tracked headcount
Investors 15 Known backers
Products 1 Services tracked
Competitors 10 Brand Intelligence

About Centivax

Centivax is a company based in San Francisco (United States) founded in 2019. Centivax has raised $92 million across 5 funding rounds from investors including NIH, US Navy and Gates Foundation. Centivax offers products and services including Broad-Spectrum Vaccine. Centivax operates in a competitive market with competitors including Medeloop, Pure Biologics, Hyku Biosciences, Sirion Biotech and Taizhou Baiying Biotechnology, among others.

  • Headquarter San Francisco, United States
  • Sectors
    Healthcare
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
Operational Areas
Healthcare → Healthcare Services & Infrastructure Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Total Equity Funding
    $92 M (USD)

    in 5 rounds

  • Latest Funding Round
    $37 M (USD), Series A

    Mar 30, 2026

  • Investors
    NIH

    & 14 more

  • Employee Count
    Not available
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Centivax

Centivax offers a comprehensive portfolio of products and services, including Broad-Spectrum Vaccine.

Product name locked
Category locked
Primary

Pre-clinical vaccine for preventing all influenza strains in animals.

People of Centivax

Headcount 10-50
Employee Profiles 13
Board Members and Advisors 14
Employee Profiles
People
Mark Bellin
Principal Scientist
People
Nicholas Bayless
CTO
People
Jacob Glanville
CEO
People
Joel Andrade
Senior Scientist

Unlock access to complete

Board Members and Advisors
people
Ted Ross
Advisor
people
William Finlay
Advisor
people
Pam Garzone
Advisor
people
Peter Moesta
Advisor

Unlock access to complete

Funding Insights of Centivax

Centivax has successfully raised a total of $92M across 5 strategic funding rounds. The most recent funding activity was a Series A round of $37 million completed in March 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in Centivax

Centivax has secured backing from 15 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include NIH, US Navy and Gates Foundation.

All
Venture Fund
Institutional
Angel
Investor Description Founded Year Domain Location
Venture capital firm offering funding and tools for startups in technology and investment sectors.
Locked Locked Locked
Future Ventures is focused on early-stage venture capital investments.
Locked Locked Locked
Early-stage life sciences and tech focused VC firm investing primarily in the US
Locked Locked Locked
Premium access

Investor details for Centivax

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Centivax

Investments
Premium access

Investment portfolio details for Centivax

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Centivax

Premium access

Detailed financials for Centivax

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Centivax Comparisons

Centivax Primary company
Description
Drug discovery services are provided to pharmaceutical and b...
Location
San Francisco, United States
Founded Year
2019
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for Centivax

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Centivax

Centivax operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Medeloop, Pure Biologics, Hyku Biosciences, Sirion Biotech and Taizhou Baiying Biotechnology, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Drug discovery services are offered by Medeloop as a CRO.
Locked Locked Locked
Specialized CRO with expertise in recombinant protein production and purification
Locked Locked Locked
Covalent medicines platform is advanced for drug discovery targeting proteins.
Locked Locked Locked
Customized AAV-based viral vectors for gene therapy are supplied.
Locked Locked Locked
Antibody-drug research and development services are provided.
Premium access

Detailed competitors of Centivax

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Centivax

Premium access

Complete news archive for Centivax

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Centivax

Centivax was founded in 2019.

Centivax is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.

Centivax is a funded company, having raised a total of $92M across 5 funding rounds to date.

Centivax was established in 2019 and is based in San Francisco, United States. Drug discovery services are offered by the company within the biotechnology sector, focusing on early-stage research and development for therapeutics. Operations include target identification, compound screening, and preclinical validation, conducted by a team leveraging the regions scientific resources. The domain centivax.com is utilized for online presence and client engagement.

Centivax's top competitors include Medeloop, Pure Biologics and Sirion Biotech.

Centivax offers Broad-Spectrum Vaccine.

Centivax has 15 investors. Key investors include NIH, US Navy, Gates Foundation, HHS, and CEPI.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available